Your browser doesn't support javascript.
loading
A strategy to improve the solubility and bioavailability of the insoluble drug piperlongumine through albumin nanoparticles.
Niu, Sen; Li, Xurui; Guo, Zhongqiu; Wan, David; Liu, Yu; Li, Li; Dong, Meng; Jia, Xirong.
Afiliação
  • Niu S; Department of Pharmaceutical Engineering, Xuzhou Pharmaceutical Higher Vocational School of Jiangsu Province, Xuzhou, China.
  • Li X; School of Pharmaceutical Sciences, Liaoning University, Shenyang, Liaoning, China.
  • Guo Z; School of Pharmaceutical Sciences, Liaoning University, Shenyang, Liaoning, China.
  • Wan D; Beijing Rule Biopharma, Co., Ltd., Beijing, China.
  • Liu Y; School of Pharmaceutical Sciences, Liaoning University, Shenyang, Liaoning, China.
  • Li L; School of Pharmaceutical Sciences, Liaoning University, Shenyang, Liaoning, China.
  • Dong M; School of Pharmaceutical Sciences, Liaoning University, Shenyang, Liaoning, China.
  • Jia X; School of Pharmaceutical Sciences, Liaoning University, Shenyang, Liaoning, China.
Pak J Pharm Sci ; 36(2): 483-490, 2023 Mar.
Article em En | MEDLINE | ID: mdl-37530156
ABSTRACT
Piperlongumine (PL) is a biologically active alkaloid derived from peppers, has significant cytotoxic effects on cancer with no cytotoxicity. This study used NabTM technology to prepare PL albumin nanoparticles (PL-BSA-NPs) to improve water solubility and bioavailability. We carried out a pharmacological evaluation of the PL-BSA-NPs. The morphological profile of the PL-BSA-NPs was relatively uniform, with an average particle size of approximately 210 nm, with drug load of 2.1% and encapsulation rate of 87.6%. PL-BSA-NPs were stable for 4 weeks when stored at 4°C. In vitro release behavior of the PL-BSA-NPs showed a sustained release, with a cumulative release of 67.24% in approximately 24 hours. The pharmacokinetic properties of PL-BSA-NPs were shown that PL-BSA-NPs could maintain a certain level of blood drug concentration for a long time, thus demonstrating the sustained release and increased bioavailability of PL. Finally, we investigated the in vitro antitumor activity of the PL-BSA-NPs and found that PL can significantly inhibit HepG2 cell proliferation, and that PL-BSA-NPs enhanced the inhibitory effect of PL on this proliferative effect. Thus, we concluded that PL can destroy liver cancer cells by increasing ROS levels. These results suggested that PL-BSA-NPs show promising potential as a targeted anti-tumor drug.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanopartículas / Antineoplásicos Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanopartículas / Antineoplásicos Idioma: En Ano de publicação: 2023 Tipo de documento: Article